|58.71||-3.36||-5.41%||Vol 1.16M||1Y Perf 103.85%|
|Sep 24th, 2021 16:00 DELAYED|
|- -||0.15 0.26%|
|Target Price||58.20||Analyst Rating||Moderate Buy 2.29|
|Potential %||-0.87||Finscreener Ranking||★★ 46.09|
|Insiders Trans % 3/6/12 mo.||-100/-100/-79||Value Ranking||★★★ 50.73|
|Insiders Value % 3/6/12 mo.||-100/-100/-52||Growth Ranking||★★ 46.11|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-51||Income Ranking||— -|
|Price Range Ratio 52W %||43.46||Earnings Rating||Strong Buy|
|Market Cap||4.01B||Earnings Date||4th Nov 2021|
Today's Price Range
5 Year PE Ratio Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th Nov 2021|
|Estimated EPS Next Report||-0.86|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.06M|
|Avg. Monthly Volume||1.43M|
|Avg. Quarterly Volume||2.01M|
Editas Medicine Inc. (NASDAQ: EDIT) stock closed at 58.71 per share at the end of the most recent trading day (a -5.41% change compared to the prior day closing price) with a volume of 1.17M shares and market capitalization of 4.01B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 235 people. Editas Medicine Inc. CEO is Cynthia Collins.
The one-year performance of Editas Medicine Inc. stock is 103.85%, while year-to-date (YTD) performance is -16.26%. EDIT stock has a five-year performance of 306.02%. Its 52-week range is between 27.01 and 99.95, which gives EDIT stock a 52-week price range ratio of 43.46%
Editas Medicine Inc. currently has a PE ratio of -24.30, a price-to-book (PB) ratio of 7.03, a price-to-sale (PS) ratio of 48.96, a price to cashflow ratio of 616.40, a PEG ratio of 2.32, a ROA of -23.03%, a ROC of -30.46% and a ROE of -31.34%. The company’s profit margin is -87.89%, its EBITDA margin is -202.80%, and its revenue ttm is $81.14 Million , which makes it $1.19 revenue per share.
Of the last four earnings reports from Editas Medicine Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.86 for the next earnings report. Editas Medicine Inc.’s next earnings report date is 04th Nov 2021.
The consensus rating of Wall Street analysts for Editas Medicine Inc. is Moderate Buy (2.29), with a target price of $58.2, which is -0.87% compared to the current price. The earnings rating for Editas Medicine Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Editas Medicine Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Editas Medicine Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 23.01, ATR14 : 3.98, CCI20 : -87.50, Chaikin Money Flow : -0.12, MACD : 0.19, Money Flow Index : 38.53, ROC : -8.72, RSI : 46.36, STOCH (14,3) : 9.57, STOCH RSI : 0.16, UO : 42.54, Williams %R : -90.43), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Editas Medicine Inc. in the last 12-months were: Charles Albright (Option Excercise at a value of $1 320 800), Charles Albright (Sold 86 000 shares of value $3 953 453 ), Cynthia Collins (Sold 2 524 shares of value $168 225 ), James C. Mullen (Buy at a value of $1 156 800), Jessica Hopfield (Buy at a value of $263 970), Michelle Robertson (Option Excercise at a value of $153 250), Michelle Robertson (Sold 6 568 shares of value $397 727 )
Tue, 24 Aug 2021 12:00 PM EST VIDEO: Editas ($EDIT) has a Big Event Coming Up! | Gene Editing Biotech
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.